Cargando…
Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic
The current COVID-19 pandemic poses numerous challenges for ongoing clinical trials and provides a stress-testing environment for the existing principles and practice of estimands in clinical trials. The pandemic may increase the rate of intercurrent events (ICEs) and missing values, spurring a grea...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117454/ https://www.ncbi.nlm.nih.gov/pubmed/33983621 http://dx.doi.org/10.1007/s43441-021-00297-6 |
_version_ | 1783691588793270272 |
---|---|
author | Qu, Yongming Lipkovich, Ilya |
author_facet | Qu, Yongming Lipkovich, Ilya |
author_sort | Qu, Yongming |
collection | PubMed |
description | The current COVID-19 pandemic poses numerous challenges for ongoing clinical trials and provides a stress-testing environment for the existing principles and practice of estimands in clinical trials. The pandemic may increase the rate of intercurrent events (ICEs) and missing values, spurring a great deal of discussion on amending protocols and statistical analysis plans to address these issues. In this article, we revisit recent research on estimands and handling of missing values, especially the ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials. Based on an in-depth discussion of the strategies for handling ICEs using a causal inference framework, we suggest some improvements in applying the estimand and estimation framework in ICH E9 (R1). Specifically, we discuss a mix of strategies allowing us to handle ICEs differentially based on reasons for ICEs. We also suggest ICEs should be handled primarily by hypothetical strategies and provide examples of different hypothetical strategies for different types of ICEs as well as a road map for estimation and sensitivity analyses. We conclude that the proposed framework helps streamline translating clinical objectives into targets of statistical inference and automatically resolves many issues with defining estimands and choosing estimation procedures arising from events such as the pandemic. |
format | Online Article Text |
id | pubmed-8117454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-81174542021-05-13 Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic Qu, Yongming Lipkovich, Ilya Ther Innov Regul Sci Analytical Report The current COVID-19 pandemic poses numerous challenges for ongoing clinical trials and provides a stress-testing environment for the existing principles and practice of estimands in clinical trials. The pandemic may increase the rate of intercurrent events (ICEs) and missing values, spurring a great deal of discussion on amending protocols and statistical analysis plans to address these issues. In this article, we revisit recent research on estimands and handling of missing values, especially the ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials. Based on an in-depth discussion of the strategies for handling ICEs using a causal inference framework, we suggest some improvements in applying the estimand and estimation framework in ICH E9 (R1). Specifically, we discuss a mix of strategies allowing us to handle ICEs differentially based on reasons for ICEs. We also suggest ICEs should be handled primarily by hypothetical strategies and provide examples of different hypothetical strategies for different types of ICEs as well as a road map for estimation and sensitivity analyses. We conclude that the proposed framework helps streamline translating clinical objectives into targets of statistical inference and automatically resolves many issues with defining estimands and choosing estimation procedures arising from events such as the pandemic. Springer International Publishing 2021-05-13 2021 /pmc/articles/PMC8117454/ /pubmed/33983621 http://dx.doi.org/10.1007/s43441-021-00297-6 Text en © The Drug Information Association, Inc 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Analytical Report Qu, Yongming Lipkovich, Ilya Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic |
title | Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic |
title_full | Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic |
title_fullStr | Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic |
title_full_unstemmed | Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic |
title_short | Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic |
title_sort | implementation of ich e9 (r1): a few points learned during the covid-19 pandemic |
topic | Analytical Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117454/ https://www.ncbi.nlm.nih.gov/pubmed/33983621 http://dx.doi.org/10.1007/s43441-021-00297-6 |
work_keys_str_mv | AT quyongming implementationofiche9r1afewpointslearnedduringthecovid19pandemic AT lipkovichilya implementationofiche9r1afewpointslearnedduringthecovid19pandemic |